Sarepta has also entered into an agreement with Arrowhead to transfer 2,660,989 shares of Arrowhead common stock in satisfaction of $50 million of the company’s previously announced $100 million milestone payment obligation
The randomized, double-blind, placebo-controlled Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102 in healthy participants
Fourteenth breakthrough therapy designation granted by FDA across the oncology portfolio of Daiichi Sankyo
Phase 1 dosing is expected to finish by the end of 2025
The collaboration will combine Firstsource’s AI-first approach with Guidehealth’s expertise in value-based care innovation
The therapy delivers the full-length ABCA4 protein and has the potential to benefit all patients with ABCA4 mutations
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Subscribe To Our Newsletter & Stay Updated